A company developing means to detect disease and monitor drug response has raised more than $20 million in a round of venture capital financing. Disease detection and monitoring company Glympse Bio has raised $ 22 m in series A funding towards developing its in urine sensing technology . The Cambridge , Massachusetts - based firm is creating technology that can be delivered to the area of diseased tissue in urine , where it can examine the area 's biological activity before emitting a signal that can be transmitted through urine . The company is currently focusing on non - alcoholic steatohepatitis , or NASH , which can lead to cirrhosis of the liver . The funding round was led by ARCH Ventures and LS Polaris Innovation Fund .
Disease detection and monitoring company Glympse Bio has raised $ 22 m in series A funding towards developing its in urine sensing technology . The Cambridge , Massachusetts - based firm is creating technology that can be delivered to the area of diseased tissue in urine , where it can examine the area 's biological activity before emitting a signal that can be transmitted through urine . The company is currently focusing on non - alcoholic steatohepatitis , or NASH , which can lead to cirrhosis of the liver . The funding round was led by ARCH Ventures and LS Polaris Innovation Fund .